Dechra acquires the rights to Malaseb^®

Friday, March 4, 2022

Dechra is pleased to announce the licensing rights of the Malaseb^® brand of dermatology products in the United States with Dermcare of Australia.

This partnership complements the existing Dechra dermatology by offering a well-known and trusted brand.

Mike Eldred, President of Dechra North America, stated, “The Malaseb line of dermatology products strengthens the popular Dechra dermatology product line by offering a brand that many veterinarians use and trust.”

About Dechra:

Dechra’s companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl^® Capsules (trilostane), Zycortal^® Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole^® Coated Tablets (methimazole), the Vetivex^® line of parenteral fluids, and Phycox^® joint health supplements. Osurnia^® (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto^®, MiconaHex+Triz^®, MalAcetic^®, and oral anti-infective product lines, including Marboquin^® (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. And the recent addition of Mirataz^® (mirtazapine transdermal ointment), Porus^® One, and Redonyl^® Ultra Feline to the portfolio supports the underserved feline market.

For questions or further information, please contact Mike Eldred or Doug Hubert:

Mike Eldred, President, North American Operations, Dechra Veterinary Products, Mike.Eldred@Dechra.com

Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products, Doug.Hubert@Dechra.com